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Abstract
Men who have sex with men (MSM) can reduce their risk of acquiring human immunodeficiency 
virus (HIV) by using various prevention strategies and by understanding the effectiveness of each 
option over the short- and long-term. Strategies examined were: circumcision; insertive anal sex 
only; consistent, 100% self-reported condom use; and pre-exposure prophylaxis (PrEP). PrEP 
efficacy was based on three levels of adherence. The cumulative HIV acquisition risk among MSM 
over periods of 1 year and 10 years were estimated with and without single and combinations of 
prevention strategies. A Bernoulli process model was used to estimate risk.
In the base case with no prevention strategies, the 1-year risk of HIV acquisition among MSM was 
8.8%. In contrast, the 1-year risk associated with circumcision alone was 6.9%; with insertive sex 
only, 5.5%; with 100% self-reported condom use, 2.7%; and with average, high, and very high 
PrEP adherence, 5.1%, 2.5%, and 0.7%, respectively. The 10-year risk of HIV acquisition among 
MSM with no prevention strategy was 60.3%. In contrast, that associated with circumcision alone 
was 51.1%; with insertive sex only, 43.1%; with 100% self-reported condom use, 24.0%; and with 
average, high, and very high PrEP adherence, 40.5%, 22.2%, and 7.2%, respectively. While MSM 
face substantial risk of HIV, there are now a number of prevention strategies that reduce risk. Very 
high adherence to PrEP alone or with other strategies appears to be the most powerful tool for HIV 
prevention.
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An estimated 1.2 million people in the United States were living with human 
immunodeficiency virus (HIV) at the end of 2013; of these, 55% were men who have sex 
with men (MSM) (1). Of the new HIV diagnoses among adults in 2013, about 68% were in 
MSM, some of whom were also injection drug users (2). Furthermore, while the annual 
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number of HIV diagnoses for all other groups decreased in 2009 – 2013, it increased among 
MSM, from 27 394 to 30 689 (2).
The majority of HIV infections among MSM occur through sexual transmission. Among 
males living with HIV, more than 70% of infections were attributable to male-to-male sexual 
contact (1). A previous analysis (3) reported on the effectiveness of single and combination 
prevention strategies over time on reducing the risk of HIV transmission among 
serodiscordant MSM and heterosexual couples. It found relatively high levels of HIV 
acquisition risk over time, unless prevention strategies were combined.
This analysis evaluated how MSM who are at risk for acquiring HIV and are unaware of 
their partner’s serostatus can reduce their risk by using single and combination prevention 
strategies. Four strategies were assessed, both singly and combined with the others: 
circumcision; insertive anal sex only, i.e., no receptive anal sex; consistent (100% 
adherence) condom use; and pre-exposure prophylaxis (PrEP). For PrEP efficacy, three 
levels were evaluated—average, high, and very high—based on observed adherence in 
clinical trials (4). Because HIV prevalence may vary widely in the communities from which 
MSM choose their partners, the analysis also examined the effectiveness of prevention 
strategies among varying prevalence rates.
MATERIALS AND METHODS
The cumulative risk of HIV acquisition among MSM over 1 year and 10 years was 
estimated. A Bernoulli process model was used to estimate HIV risk without a prevention 
strategy in the base case (see Supplementary Materials; 3, 5); then the base case estimate 
was adjusted with each risk-reduction strategy separately and in combination. Risk ratios 
were assumed to be independent and multiplicative in assessing risk reduction with 
combination strategies (3, 6). The key input parameters used in the model included per-act 
HIV transmission probabilities with insertive and receptive anal sex, HIV risk-reduction 
strategies or risk modifiers, number of sex acts, and HIV prevalence among MSM partners 
(see Supplementary Materials). The analyses were conducted with Microsoft Excel™ 
(Microsoft Corp., Redmond, Washington, United States).
The input values used in the analysis for the per-act HIV transmission probability associated 
with unprotected (no condom use) insertive and receptive anal sex, the average number of 
sex acts per month (three insertive and three receptive anal sex acts per month), and the 
efficacy of male circumcision applied to only insertive anal acts have been described by 
Lasry and colleagues (3). An 18% (3% – 43%) HIV prevalence among sex partners was used
—based on anonymous HIV testing of MSM in the 2011 National HIV Behavioral 
Surveillance System, a survey of MSM recruited through venue-based sampling in 
metropolitan statistical areas of the United States (7). The analysis assumed that 30% of 
MSM living with HIV would adhere to antiretroviral therapy (ART) and have a suppressed 
HIV ribonucleic acid (RNA) viral load, conferring on this model a 96% reduction in HIV 
transmission (8, 9).
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An efficacy of 70% (95% Confidence Interval [95%CI]: 58% – 79%) was applied to 100% 
condom use, based on analyses of data from two HIV prevention trials in the United States 
that enrolled HIV- uninfected MSM (10). No efficacy was assumed if condoms were used 
less than 100% of the time, based on results from the same study. Three levels of adherence 
to PrEP were used based on the iPrEX trial results (4): average, as reported in an intention-
to-treat analysis; high, based on pill count; and very high, based on study drug (emtricitabine 
and tenofovir disoproxil fumarate [FTC/TDF]) detection in blood samples. The 
corresponding efficacies were 44% (95% CI: 15% – 63%), 73% (95% CI: 41% – 88%), and 
92% (95% CI: 40% – 99%), respectively (4).
Univariate sensitivity analysis on two parameters were conducted to explore potential 
variation in the risk estimates (see Supplementary Materials). The possibly wide variation in 
prevalence among the communities from which MSM may select their partners was 
explored. In addition, previous analyses have demonstrated that the number of HIV 
exposures—sex acts in this analysis—has a large effect on the risk of acquiring HIV. 
Therefore, similar to Lasry and colleagues (3), in this study the number of sex acts was 
assumed to vary from 2 – 20 per month, compared to the base case value of 6.
RESULTS
In the base case with no prevention strategies, the 1-year risk of HIV acquisition among 
MSM was 8.8% (Figure 1). In contrast, the 1-year risk associated with circumcision alone 
was 6.9%; with insertive sex only, 5.5%; with 100% self- reported condom use, 2.7%; and 
with average, high, and very high PrEP adherence, 5.1%, 2.5%, and 0.7%, respectively.
In the base case with no prevention strategies, the 10-year risk of HIV acquisition among 
MSM was 60.3% (Figure 2). In contrast, the 10-year risk associated with circumcision alone 
was 51.1%; with insertive sex only, 43.1%; with 100% self-reported condom use, 24.0%; 
and with average, high, and very high PrEP adherence, 40.5%, 22.2%, and 7.2%, 
respectively.
The most effective prevention combination—very high PrEP adherence, 100% condom use, 
circumcision, and insertive sex only—reduced 1-year acquisition risk to 0.04% and 10-year 
risk to 0.4%. The efficacy of other combinations of prevention strategies are presented in 
Figures 1 and 2.
When the adjusted HIV prevalence varied from 3% – 43% (base case: 18%), the 1-year HIV 
acquisition risk without prevention strategies ranged from 1.5% – 19.9% (base case risk: 
8.8%; data not shown). With high adherence to PrEP, the 1-year acquisition risk ranged from 
0.4% – 5.8% (base case risk: 2.5%).
When the number of sex acts per month varied from 2 – 20 (base case: 6), the 1-year HIV 
acquisition risk without prevention strategies ranged from 3.1% – 25.7% (base case risk: 
8.8%). With high adherence to PrEP, the 1-year acquisition risk ranged from 0.8% – 8.0% 
(base case risk: 2.5%).
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DISCUSSION
The risk of HIV acquisition was high among MSM in this analysis when no prevention 
strategies were employed, reaching 60% after 10 years of continuous exposure. At the 
highest level of adherence, PrEP was the single most protective strategy. However, at the 
average level of adherence—the level of adherence associated with the modified intention-
to-treat analysis in the iPrEX trial (4)—PrEP was less protective than condoms alone when 
condoms were used to cover all sex acts. Combinations of strategies also were usually very 
protective, even among those not based on PrEP; for instance, circumcision among men who 
also practiced only insertive sex, decreased risk substantially.
High levels of adherence can be difficult to achieve. In the iPrEX trial on pre-exposure 
prophylaxis among MSM in several countries, only 51% of participants had a detectable 
level of the study drug in their blood sample, and for that group, PrEP was 92% efficacious 
(4). The overall efficacy of PrEP in iPrEX was 44% among participants with and without 
detectable drug in their blood sample. An iPrEX subgroup analysis evaluated adherence to 
the study drug among 510 participants. Of the 56 participants from the United States, 95% 
had any detectable levels of the study drug, and 57% had drug levels associated with 
consistent dosing (11). A multi-site demonstration project implemented in sexually-
transmitted disease and community health clinics in the United States found 65% of the 
study participants had drug levels consistent with taking four or more doses per week, at all 
visits (12).
Furthermore, MSM frequently report less than 100% condom use. In the 2011 National HIV 
Behavioral Surveillance System (13), 57% of MSM who reported being HIV-negative or of 
unknown status, also reported having had anal sex in the prior 12 months without a condom 
and with a partner of any HIV status, i.e., positive, negative, or unknown (13). Among MSM 
who considered themselves HIV-negative, but tested positive, 33% reported that their most 
recent sex act was anal sex, unprotected by a condom and with a male partner of HIV-
negative or unknown status. Among MSM who tested HIV-negative, 12% reported that their 
most recent sex act was anal sex unprotected by a condom with a male partner of HIV-
positive or unknown status. Smith and colleagues found in their analyses of condom use and 
efficacy in 3 490 HIV-negative MSM, 35% of those having anal sex with a male partner of 
any HIV status reported sex without a condom at least once during any 6-month interval, as 
did 84% over all 6-month intervals assessed (10). In theory, use of condoms for some, even 
if not all sex acts should provide some protection from HIV. However, trials of condom 
effectiveness, where adherence can only be measured through self-report, have not 
demonstrated partial effectiveness.
Sensitivity analyses showed that the study results would be affected by the prevalence of 
HIV in the communities from which men choose partners, and the average number of sex 
acts. Higher prevalence and more sex acts both resulted in greater risk.
Limitations
This analysis has several limitations. Although the relative magnitude of effect would remain 
unchanged for the single and combination strategies assessed, a number of factors could 
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alter absolute risk levels, including a change in the proportion of MSM in a community who 
have achieved viral load suppression and the increase or decrease in number and type of sex 
acts over time. In assessing combination strategies, we assumed that risk ratios were 
independent and multiplicative (3, 6). While it is possible that the efficacy of combined 
interventions would not be multiplicative, insufficient data were available to assess other 
possibilities. Furthermore, we assumed no change in risk behavior for the individual base 
case when estimating 10-year HIV acquisition risks under single or combinations of 
prevention strategies.
We attributed the protective effect of male circumcision to insertive sex acts, assuming a 
biological equivalence with insertive vaginal sex. However, because none of the randomized 
controlled trials of male circumcision included many MSM, definitive statements regarding 
the effect of male circumcision on the risk of acquiring HIV or other sexually transmitted 
infections cannot be made. In this analysis, where 50% of anal sex acts were assumed to be 
insertive and 50% receptive, the greater per-act transmission risk associated with receptive 
anal sex dwarfed the effect of circumcision, and circumcision alone reduced the 10-year risk 
of HIV acquisition from 60.3% to only 51.1%.
Lastly, this analysis does not factor in access, affordability, or cost differences between the 
different strategies, which could affect uptake among MSM. This analysis was designed to 
provide MSM with a measure of the potential benefits of HIV prevention strategies. 
However, individual decisions regarding these strategies could also be shaped by perceptions 
and understandings of HIV risk, potential stigma associated with engaging in HIV 
prevention efforts, perceived side effects, and adherence challenges.
Conclusions
In conclusion, while MSM face a substantial risk of acquiring HIV, they also may be able to 
access a number of prevention strategies to reduce that risk. Combinations of strategies 
generally work better than single strategies. Very high adherence to PrEP, either alone or 
combined with other strategies, may be the most powerful tool for HIV prevention. Analyses 
such as this one improve our understanding of HIV acquisition risk over the short- and long-
term, and assist MSM in choosing prevention strategies best suited to personal preferences 
and circumstances.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Annual risk of Human Immunodeficiency Virus (HIV) acquisition among HIV-uninfected 
males who have sex with males, using combinations of prevention strategies—condom 
(CON), pre-exposure prophylaxis (PrEP), circumcision (Circ), insertive anal sex only (IAS)
—or no strategy (base case), United States of America, 2015
Source: Prepared by the authors from the study data.
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FIGURE 2. 
The 10-year risk of Human Immunodeficiency Virus (HIV) acquisition among HIV-
uninfected males who have sex with males, using combinations of prevention strategies—
condom (CON), pre-exposure prophylaxis (PrEP), circumcision (Circ), insertive anal sex 
only (IAS)—or no strategy (base case), United States of America, 2015
Source: Prepared by the authors from the study data.
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